Navigation Links
Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)

VEDBAEK, Denmark, August 28 /PRNewswire-FirstCall/ -- Strong organic growth continued in Q2 2008 supported by new research product offerings. The development of Exiqon's first molecular diagnostic product based on miRNA profiling remains on track for year end launch.

- Revenue in Q2 2008 increased by 139% on the year-earlier period to DKK

28 million, totaling DKK 44.5 million in the first six months of 2008.

- Product sales in Q2 2008 increased by 239% on the same period last year

to DKK 26.3 million (including research product sales and diagnostic

sales) totaling DKK 40.5 million in the first six months of 2008.

Research product sales grew organically by 70% compared to Q2 2007.

- Direct contribution margin in Q2 2008 was 65% compared to 78% in the

same period last year, totaling 66% in the first six months of 2008.

Gross margin was 25% compared to 64% in the same period last year,

totaling 33% in the first six months of 2008. The gross margin was

affected by new product offerings and cost of unused capacity during the

current build-up phase.

- Total operating expenses in Q2 2008 increased by 80% on the same period

last year to DKK 48.3 million, totaling DKK 82.7 million in the first six

months of 2008. The increase in operating expenses is primarily due to

the acquisition of Oncotech Inc.

- Net loss for Q2 2008 was DKK 38.8, totaling DKK 63.5 million the first

six months of 2008. EPS amounted to DKK -1.37 in Q2 2008 and DKK -2.25 in

the first six months of 2008.

- Based on current activities, the financial guidance for 2008

is retained with revenue of DKK 140-150 million in 2008 including both

research product sales and diagnostic sales. A net loss of DKK 100-115

million is expected, for the full year 2008, including the effect of

costs of current incentive plans in the amount to DKK 6 million.


Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
2. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
3. Exiqon: Major Shareholder Announcement
4. Arpida Reports Interim Results for Six Months to 30 June 2008
5. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
6. LPBP Inc. - Re-filing certification of interim filings
7. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
10. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Sigma-Aldrich Corporation (NASDAQ: ... ® brand within its Applied Diagnostics and ... acid reference standards product line with ten certified ... tested bile acids and their stable-labeled internal standards. ... of lithocholic acid, taurocholic acid and native and ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS Neurosciences, ... agreement to develop and commercialize intellectual property rights belonging to The University of ... 2009, and affords exclusive worldwide rights to intellectual property based on use of ...
(Date:10/7/2015)... PUNE, India , October 8, 2015 ... --> Medical biotechnology accounts for ... use of bioinformatics in drug discovery and ... with . ... --> On the basis of applications, ...
(Date:10/7/2015)... ... October 07, 2015 , ... Neil Riordan, PhD to Discuss ... Tomorrow, October 8th, at Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan ... therapy. , He is the Co-Founder and Chief Science Officer of the ...
Breaking Biology Technology:
... the first time observed chemical reactions near absolute zero, ... that reaction rates can be controlled using quantum mechanics, ... results and techniques, described in the Feb. 12 issue ... unknown aspects of how molecules interact, a key to ...
... , CINCINNATI , ... it will release its fourth quarter and full-year 2009 financial results after ... will host a telephone conference call and simultaneous webcast on Thursday, ... and answer session will follow. , Conference Call Instructions ...
... , , , ... /PRNewswire-Asia/ -- The January issue of,"Neuropharmacology", publishes the article ... (MLC 601) protective effects on neuronal and brain,injuries as well ... The French research team was led by Prof. ...
Cached Biology Technology:
(Date:10/5/2015)... 2015 ) ... Inc. (NASDAQ: NXTD ), a biometric authentication company ... ) releases the following market ... ), a biometric authentication company focused on the growing ... ( ) releases the following market ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court of ... another key ruling in favor of Crossmatch ™, ... fingerprint scanner company Suprema and its U.S. partner Mentalix ... a trade provision that declares it unlawful to engage ... infringing two of Crossmatch,s patents, the 5,900,993 patent and ...
(Date:9/28/2015)... 28, 2015 CLEAR, the leading ... expedited traveler service is coming to Austin-Bergstrom ... bringing a frictionless experience, serious speed and ... "CLEAR offers our travelers an expedited security ... Jim Smith , Executive Director, Austin-Bergstrom ...
Breaking Biology News(10 mins):
... more species in the tropics than in the temperate regions ... the tropics (perhaps more than half), but the reason has ... researchers have hypothesized that climatic factors somehow cause species to ... in the November issue of The American Naturalist, John Wiens ...
... the ironic name "Srcasm" can counteract the effects of ... by investigators at the University of Pennsylvania School of ... acts like a brake in epithelial cells, preventing uncontrolled ... Src kinases. This finding, published online in the Journal ...
... been a key factor in why the human brain ... a study comparing the genomes of humans, chimpanzees, mice ... Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and Joint ... genetic differences in DNA sequences that appear to regulate ...
Cached Biology News:
Request Info...
... Maintenance 112 days/each , ... injections x5 /each , Test ... Production bleed (25 ml blood =12 ml serum) ... blood (~50 ml serum) x1 each , free ...
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
Biology Products: